deferoxamine has been researched along with Fanconi Anemia in 5 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Management of these patients requires proper dosing of desferrioxamine and transfusion therapy, along with regular monitoring of body iron burden and hemoglobin." | 1.30 | Desferrioxamine ototoxicity in an adult transfusion-dependent population. ( Alberti, PW; Chiodo, AA; Francombe, WH; Sher, GD; Tyler, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voter, AF | 1 |
| Manthei, KA | 1 |
| Keck, JL | 1 |
| Chiodo, AA | 1 |
| Alberti, PW | 1 |
| Sher, GD | 1 |
| Francombe, WH | 1 |
| Tyler, B | 1 |
| Schmitt, K | 1 |
| Tulzer, W | 1 |
| Poot, M | 1 |
| Hoehn, H | 1 |
| Porfirio, B | 1 |
| Ambroso, G | 1 |
| Giannella, G | 1 |
| Isacchi, G | 1 |
| Dallapiccola, B | 1 |
5 other studies available for deferoxamine and Fanconi Anemia
| Article | Year |
|---|---|
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanc | 2016 |
Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Topics: Adult; Aged; Anemia, Sickle Cell; Audiometry; beta-Thalassemia; Deferoxamine; Drug Monitoring; Fanco | 1997 |
[Rare indications for iron chelation therapy with desferrioxamine].
Topics: Adolescent; Anemia, Dyserythropoietic, Congenital; Chelation Therapy; Deferoxamine; Dose-Response Re | 1991 |
Partial correction of chromosome instability in Fanconi anemia by desferrioxamine.
Topics: Anemia, Aplastic; Chromosome Aberrations; Deferoxamine; Fanconi Anemia; Humans; Lymphocytes | 1990 |
Partial correction of chromosome instability in Fanconi anemia by desferrioxamine.
Topics: Anemia, Aplastic; Cells, Cultured; Chromosome Aberrations; Chromosomes, Human; Deferoxamine; Epoxy C | 1989 |